Grade: Pharmaceutical Grade

Factory Location: Lianyungang，Jiang su，China

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as aninhalational anaesthetic for induction and maintenance of general anesthesia. After Desflurane, it is the volatile anesthetic with the fastest onset and offset. It is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, across all ages, as well as in veterinary medicine. Together with Desflurane, Sevoflurane is replacing isoflurane and halothane in modern anesthesiology. It is often administered in a mixture of nitrous oxideand oxygen.
Sevoflurane API has got Chinese local GMP certificate, and has been approved by US-FDA. EDMF is also available.
Sevoflurane Inhalation Anesthetic was approved by CFDA and launched in Chinese market in 2007 which is used in the induction and maintenance of the general anesthetic of pediatric in-patient and out-patient surgery. In November 2015, it was approved by US FDA and launched in US market and in 2016 got the approval to get launched in EU. 
The sales of Sevoflurane have covered over 10 countries in South America, Asia and the Middle East.